Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-11-18 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
第二期员工持股计划管理办法
Capital/Financing Update Classification · 95% confidence The document is titled "深圳华大基因股份有限公司 第二期员工持股计划管理办法" which translates to "Shenzhen BGI Genomics Co., Ltd. Second Employee Stock Ownership Plan Management Measures." The content details the rules, principles, management, rights, obligations, and procedures related to an employee stock ownership plan (ESOP). It includes information on stock purchase price, lock-up periods, performance assessments, management committees, and rights and obligations of the company and plan participants. There is no indication that this is a financial report like an annual or interim report, earnings release, or audit report. It is not a call transcript, nor a voting result announcement. It is a detailed regulatory and governance document about the employee stock ownership plan, which is a form of capital/financing update related to share repurchases and employee incentives. The document is lengthy and substantive, not a brief announcement or a certification. Therefore, the best fitting category is Capital/Financing Update (CAP), as it relates to the company's financing activities through employee stock ownership plans and share repurchases for that purpose.
2022-11-18 Chinese
2022年限制性股票激励计划首次授予激励对象名单
Remuneration Information Classification · 95% confidence The document is titled as a list of recipients for a 2022 restricted stock incentive plan from Shenzhen BGI Genomics Co., Ltd. It details the names and positions of management and core business personnel who are granted restricted stock under the incentive plan. The content is a detailed announcement of the allocation of stock incentives to individuals, which relates to management compensation and share-based incentives. There is no indication of financial statements, audit information, voting results, or other report types. This type of document is best classified under Remuneration Information (DEF 14A), as it details compensation-related stock incentive grants to management and key personnel.
2022-11-18 Chinese
2022年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled '2022 年限制性股票激励计划实施考核管理办法' which translates to '2022 Restricted Stock Incentive Plan Implementation Assessment Management Measures'. It details the rules, principles, assessment criteria, and procedures for the company's restricted stock incentive plan for management and core personnel. The content focuses on the internal management and performance evaluation related to stock incentives, including performance targets, assessment periods, and organizational responsibilities. There is no indication that this is a financial report, earnings release, or regulatory filing. It is not an announcement of voting results, nor a proxy statement, nor a remuneration report. It is a governance-related document outlining internal policies and procedures related to stock incentives and performance assessment. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3672 characters, which is relatively short but contains substantive policy content rather than just an announcement or notice, so it is not RPA or RNS.
2022-11-18 Chinese
国浩律师（深圳）事务所关于深圳华大基因股份有限公司第二期员工持股计划之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding Shenzhen BGI Genomics Co., Ltd.'s second employee stock ownership plan. It extensively discusses the legal compliance, procedures, and regulatory adherence of the employee stock ownership plan, including detailed legal analysis and confirmation of the plan's legitimacy and compliance with relevant laws and regulations. It is not a financial report, earnings release, or management discussion but a legal opinion related to a specific corporate action (employee stock ownership plan). This type of document is best classified as a Regulatory Filing (RNS) because it is a legal opinion letter and does not fit into other categories such as Annual Report, Audit Report, or Capital/Financing Update. The document length is substantial and contains detailed legal content, not merely an announcement or certification. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2022-11-18 Chinese
国浩律师（深圳）事务所关于深圳华大基因股份有限公司二〇二二年限制性股票激励计划之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding Shenzhen BGI Genomics Co., Ltd.'s 2022 restricted stock incentive plan. It extensively discusses the terms, conditions, legal compliance, procedures, and implications of the stock incentive plan. The content focuses on the legal aspects of a stock-based employee incentive program, including definitions, implementation conditions, approval processes, and compliance with regulatory requirements. This type of document is a legal opinion related to a capital/financing activity, specifically a stock incentive plan, which falls under updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report, nor a full financial report, but a legal opinion on a capital-related plan. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is not a mere announcement or certification but a substantive legal opinion on a financing-related matter.
2022-11-18 Chinese
关于独立董事公开征集表决权的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a public announcement by an independent director of Shenzhen BGI Genomics Co., Ltd. regarding the solicitation of voting rights for proposals to be considered at the company's 2022 fifth extraordinary general meeting of shareholders. It details the legal basis, procedures, and authorization forms for shareholders to delegate their voting rights to the independent director for specific proposals related to a 2022 restricted stock incentive plan and employee stock ownership plans. The document is not a report of financial results, audit, or management discussion, nor is it a proxy solicitation statement or voting results declaration. Instead, it is an announcement about the solicitation of voting rights by an independent director, which is a specific type of shareholder communication related to voting rights. This fits best under the category of "Declaration of Voting Results & Voting Rights Announcements (DVA)" as it concerns the public solicitation of voting rights for shareholder meeting proposals.
2022-11-18 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.